Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Charles River Laboratories International Inc (NYSE: CRL) closed at $156.68 in the last session, up 0.56% from day before closing price of $155.8. In other words, the price has increased by $0.56 from its previous closing price. On the day, 1.04 million shares were traded. CRL stock price reached its highest trading level at $158.02 during the session, while it also had its lowest trading level at $156.45.
Ratios:
We take a closer look at CRL’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 42.09 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.33. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.83.
On May 23, 2025, Redburn Atlantic Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $182.
TD Cowen Upgraded its Hold to Buy on May 14, 2025, while the target price for the stock was maintained at $179.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 07 ’25 when LaPlume Joseph W sold 400 shares for $150.04 per share. The transaction valued at 60,016 led to the insider holds 24,916 shares of the business.
Joseph LaPlume bought 400 shares of CRL for $60,000 on Aug 07 ’25. On Jul 21 ’25, another insider, WALLMAN RICHARD F, who serves as the Former Director of the company, bought 8,500 shares for $150.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRL now has a Market Capitalization of 7710880256 and an Enterprise Value of 10363288576. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.91 while its Price-to-Book (P/B) ratio in mrq is 2.30. Its current Enterprise Value per Revenue stands at 2.572 whereas that against EBITDA is 10.844.
Stock Price History:
The Beta on a monthly basis for CRL is 1.47, which has changed by -0.23203605 over the last 52 weeks, in comparison to a change of 0.15005577 over the same period for the S&P500. Over the past 52 weeks, CRL has reached a high of $230.02, while it has fallen to a 52-week low of $91.86. The 50-Day Moving Average of the stock is 0.11%, while the 200-Day Moving Average is calculated to be -3.08%.
Shares Statistics:
According to the various share statistics, CRL traded on average about 902.09K shares per day over the past 3-months and 1229490 shares per day over the past 10 days. A total of 49.21M shares are outstanding, with a floating share count of 48.66M. Insiders hold about 1.12% of the company’s shares, while institutions hold 111.26% stake in the company. Shares short for CRL as of 1753920000 were 2187117 with a Short Ratio of 2.42, compared to 1751241600 on 2396606. Therefore, it implies a Short% of Shares Outstanding of 2187117 and a Short% of Float of 5.11.
Earnings Estimates
The dynamic stock of Charles River Laboratories International Inc (CRL) is currently attracting attention from 12.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $2.38, with high estimates of $2.54 and low estimates of $2.23.
Analysts are recommending an EPS of between $10.48 and $9.79 for the fiscal current year, implying an average EPS of $10.17. EPS for the following year is $10.72, with 16.0 analysts recommending between $11.72 and $10.25.
Revenue Estimates
According to 10 analysts, the current quarter’s revenue is expected to be $982.73M. It ranges from a high estimate of $1.01B to a low estimate of $954.6M. As of the current estimate, Charles River Laboratories International Inc’s year-ago sales were $1.01BFor the next quarter, 10 analysts are estimating revenue of $980.88M. There is a high estimate of $1.01B for the next quarter, whereas the lowest estimate is $964.26M.
A total of 14 analysts have provided revenue estimates for CRL’s current fiscal year. The highest revenue estimate was $4.05B, while the lowest revenue estimate was $3.89B, resulting in an average revenue estimate of $3.98B. In the same quarter a year ago, actual revenue was $4.05BBased on 14 analysts’ estimates, the company’s revenue will be $4.06B in the next fiscal year. The high estimate is $4.17B and the low estimate is $3.93B.
